Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P10 vs Rituxan in Low Tumour Burden Follicular Lymphoma
NCT02260804Phase 3Completed
- Sponsor
- Celltrion
- Start
- Nov 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in follicular lymphoma (FL), sponsored by Celltrion. Started Nov 2015; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02260804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260804.